SHATTUCK LABS INC (STTK)
US82024L1035 - Common Stock
STTK gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 582 industry peers in the Biotechnology industry. STTK has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, STTK is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year STTK has reported negative net income.
In the past year STTK has reported a negative cash flow from operations.
STTK had negative earnings in each of the past 5 years.
In the past 5 years STTK always reported negative operating cash flow.
1.2 Ratios
STTK's Return On Assets of -58.14% is in line compared to the rest of the industry. STTK outperforms 41.62% of its industry peers.
With a Return On Equity value of -66.05%, STTK perfoms like the industry average, outperforming 56.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -58.14% | ||
| ROE | -66.05% | ||
| ROIC | N/A |
ROA(3y)-39.81%
ROA(5y)-36.64%
ROE(3y)-44.91%
ROE(5y)-62.38%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
STTK does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
STTK does not have a ROIC to compare to the WACC, probably because it is not profitable.
STTK has more shares outstanding than it did 1 year ago.
STTK has more shares outstanding than it did 5 years ago.
STTK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
STTK has an Altman-Z score of 7.90. This indicates that STTK is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 7.90, STTK belongs to the best of the industry, outperforming 83.42% of the companies in the same industry.
There is no outstanding debt for STTK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.9 |
ROIC/WACCN/A
WACC9.19%
2.3 Liquidity
A Current Ratio of 9.15 indicates that STTK has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 9.15, STTK is in the better half of the industry, outperforming 73.75% of the companies in the same industry.
A Quick Ratio of 9.15 indicates that STTK has no problem at all paying its short term obligations.
STTK has a better Quick ratio (9.15) than 73.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.15 | ||
| Quick Ratio | 9.15 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 16.81% over the past year.
The Revenue has grown by 282.96% in the past year. This is a very strong growth!
STTK shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -40.62% yearly.
EPS 1Y (TTM)16.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.49%
Revenue 1Y (TTM)282.96%
Revenue growth 3Y-44.95%
Revenue growth 5Y-40.62%
Sales Q2Q%1856.14%
3.2 Future
STTK is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.12% yearly.
Based on estimates for the next years, STTK will show a very strong growth in Revenue. The Revenue will grow by 109.00% on average per year.
EPS Next Y22.13%
EPS Next 2Y8.96%
EPS Next 3Y-2.35%
EPS Next 5Y4.12%
Revenue Next Year69.16%
Revenue Next 2Y53.24%
Revenue Next 3Y28.6%
Revenue Next 5Y109%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
STTK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for STTK. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as STTK's earnings are expected to decrease with -2.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.96%
EPS Next 3Y-2.35%
5. Dividend
5.1 Amount
STTK does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SHATTUCK LABS INC
NASDAQ:STTK (5/31/2024, 7:07:41 PM)
After market: 7.38 0 (0%)7.38
-0.03 (-0.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap350.92M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -58.14% | ||
| ROE | -66.05% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 9.15 | ||
| Quick Ratio | 9.15 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)16.81%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y22.13%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)282.96%
Revenue growth 3Y-44.95%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y